74
Participants
Start Date
May 17, 2018
Primary Completion Date
November 29, 2018
Study Completion Date
February 26, 2019
Vericiguat (BAY1021189)
A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat
Moxifloxacin
D: 400 mg moxifloxacin
Placebo
A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
Charité Campus Virchow-Klinikum (CVK), Berlin
PAREXEL GmbH, Berlin
Medizinische Einrichtungen der Universität Bonn, Bonn
Universitätsklinikum Heidelberg, Heidelberg
Universitätsherzzentrum Freiburg - Bad Krozingen, Bad Krozingen
SocraTec R&D Clinical Ward, Erfurt
IMSP Republican Clinical Hospital, Chisinau
Center for Human Drug Research, Leiden
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Bayer
INDUSTRY